Nimenrix meningitis vaccine edges closer to the market for GSK

The European Medicines Agency has recommended approval for GlaxoSmithKline's ($GSK) conjugate vaccine against meningococcal disease in adults and children from the age of 12 months. The active vaccine targets Neisseria meningitidis groups A, C, W-135 and Y. The Committee for Medicinal Products for Human Use (CHMP) said it "considers there to be a favorable benefit-to-risk balance for Nimenrix and therefore recommends the granting of the marketing authorization." Thomas Breuer, senior vice president and head of global vaccine development at GSK, commented: "GSK has over 20 years experience in developing meningococcal vaccines. This positive opinion represents a major milestone in our development program and we look forward to receiving the final decision from the EMA in the coming months." Press release | EMA summary (.pdf)

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.